EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review

Heba Saed El-Amawy

Anais Brasileiros de Dermatologia · 2026-01 · 101 (1) · 501255

DOI: 10.1016/j.abd.2025.501255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anais Brasileiros de Dermatologia, 2026-01. Verfasst von Heba Saed El-Amawy. Beteiligte Einrichtung: Department of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt. Electronic address: hebasaed88@gmail.com. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Skin Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tanta University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist. Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023, and has demonstrated significant efficacy in glycemic control and weight reduction. Beyond its metabolic benefits, recent evidence highlights its relevance in dermatology. This review explores the dermatologic implications of tirzepatide, including its cutaneous adverse effects, therapeutic potential in inflammatory skin diseases, and cosmetic benefits. Cutaneous side effects such as hypersensitivity reactions, injection-site reactions, and rare severe dermatologic events have been documented. Across the SURPASS clinical trials, injection-site reactions occurred slightly more frequently, comparable to other GLP-1 receptor agonists as semaglutide. Meanwhile, tirzepatide's immunomodulatory properties suggest potential therapeutic roles in conditions like psoriasis and hidradenitis suppurativa; however, current evidence is limited to case reports and small studies. Additionally, its profound effects on fat distribution raise interest in its cosmetic implications. Tirzepatide's induced rapid weight loss may lead to aesthetic changes, including facial volume loss, which warrants cautious interpretation. This narrative review summarizes current data from clinical trials, case reports, and pharmacovigilance sources, based on a literature search of PubMed, Scopus, and Google Scholar up to May 2025, focusing on skin-related adverse events, therapeutic effects, and cosmetic outcomes of tirzepatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric Inhibitory PolypeptideSkin DiseasesHumansGlucagon-Like Peptide-1 Receptor AgonistsTirzepatide

Stichwörter der Autor:innen

Glucagon-like peptide-1 receptor agonistsSkinTirzepatideTirzepatide /adverse effectsTirzepatide/therapeutic use

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsTirzepatide

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt. Electronic address: hebasaed88@gmail.com.

Förderung

  • Tanta University

Zitieren

APA

El-Amawy, H. S. (2026). Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review. Anais Brasileiros de Dermatologia, 101(1), 501255. https://doi.org/10.1016/j.abd.2025.501255

Vancouver

El-Amawy HS. Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review. Anais Brasileiros de Dermatologia. 2026;101(1):501255. doi:10.1016/j.abd.2025.501255

BibTeX
@article{ElAmawy2026,
  author = {El-Amawy, Heba Saed},
  title = {Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – A comprehensive review},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2026},
  volume = {101},
  number = {1},
  pages = {501255},
  doi = {10.1016/j.abd.2025.501255}
}
Kostenlos starten →